Maggio M, Lauretani F, De Vita F, Buttò V, Cattabiani C, Masoni S, Sutti E, Bondi G, Dall'aglio E, Bandinelli S, Corsonello A, Abbatecola A M, Lattanzio F, Ferrucci L, Ceda G P
M. Maggio, MD, PhD, Department of Clinical and Experimental Medicine, Geriatric Clinic, Food Sciences Unit and Endocrinology of Aging Unit, via Gramsci 14, 43100, Parma, Italy. Phone: 0039-0521-703916 E-Mail:
J Nutr Health Aging. 2014 Apr;18(4):420-3. doi: 10.1007/s12603-013-0430-z.
to investigate the effects of proton pump inhibitors (PPIs) on the insulin-like-growth factor 1(IGF-1) system in the elderly.
cross-sectional.
InCHIANTI study.
938 older subjects (536 women, 402 men, mean age 75.7±7.4 years).
complete data on age, sex, BMI, liver function, medications, dietary intake, IGF-1, IGF-binding protein-1 and -3 (IGFBP-1, IGFBP-3).
Participants were categorized by PPI use, identifying 903 PPI non users and 35 users. After adjusting for age, male PPI users (107.0 ± 69.6 vs. 127.1 ± 55.8, p<0.001) and female PPI users (87.6 ± 29.1 vs. 107.6 ± 52.3, p=0.03) had lower IGF-1 levels than non-users. IGFBP-1 levels were similar in the two groups in both sexes. In whole population, after adjustment for age and sex, PPI users had lower IGF-1 levels 81.9 [61.1-113.8] than non-users 110 [77.8-148.6], p=0.02. After further adjustment for BMI, albumin, liver function, C-reactive protein, Interleukin-6, number of medications, ACE-inhibitors use, caloric intake, protein intake, physical activity, glycemia, and IGFBP-1, the use of PPIs remained significantly and negatively associated with IGF-1 levels (β±SE = -19.60±9.83, p=0.045).
Use of PPIs was independently and negatively associated with IGF-1 levels.
研究质子泵抑制剂（PPIs）对老年人胰岛素样生长因子1（IGF-1）系统的影响。
横断面研究。
InCHIANTI研究。
938名老年受试者（536名女性，402名男性，平均年龄75.7±7.4岁）。
年龄、性别、体重指数、肝功能、用药情况、饮食摄入量、IGF-1、胰岛素样生长因子结合蛋白-1和-3（IGFBP-1、IGFBP-3）的完整数据。
根据是否使用PPIs对参与者进行分类，确定903名未使用PPIs者和35名使用者。在调整年龄后，男性PPI使用者（107.0±69.6 vs. 127.1±55.8，p<0.001）和女性PPI使用者（87.6±29.1 vs. 107.6±52.3，p=0.03）的IGF-1水平低于未使用者。两组男女的IGFBP-1水平相似。在整个人口中，调整年龄和性别后，PPI使用者的IGF-1水平为81.9[61.1-113.8]，低于未使用者的110[77.8-148.6]，p=0.02。在进一步调整体重指数、白蛋白、肝功能、C反应蛋白、白细胞介素-6、用药数量、血管紧张素转换酶抑制剂使用情况、热量摄入、蛋白质摄入、身体活动、血糖和IGFBP-1后，PPIs的使用与IGF-水平仍存在显著负相关（β±SE=-19.60±9.83，p=0.045）。
PPIs的使用与IGF-1水平独立且呈负相关。
